FDC LIMITED
FDC · Pharma · NSE
₹422
Current Market Price
Fair Value (DCF)
₹545
Discount to FV
+29.1%
Updated just now
YieldIQ Score
59/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
57%
ROE
11.3%
Debt/Equity
0.01
WACC
9.7%
Market Cap
₹6,871 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.5%
Return on capital employed
EV / EBITDA
11.8×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
96.8×
EBIT covers interest
Current Ratio
3.01×
Short-term liquidity
Asset Turnover
0.71×
Revenue per ₹ of assets
Revenue CAGR (3Y)
6.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹422
Bear case
Discount -27.6%
Base case
Discount +22.5%
Bull case
Discount +42.7%
Ratio Trends
FDC · last 9 annual periods
ROE
11.3%
ROCE
17.5%
Operating Margin
—
Debt / Equity
0.01×
PE
18.6×
EV / EBITDA
11.8×
Historical Financials
FDC · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1523 Cr | ₹1778 Cr | ₹1935 Cr | ₹2108 Cr | ₹2171 Cr | +9.3% |
| EBITDA | ₹329 Cr | ₹300 Cr | ₹440 Cr | ₹415 Cr | ₹439 Cr | +7.5% |
| EBIT | ₹292 Cr | ₹262 Cr | ₹400 Cr | — | — | +8.2% |
| PAT | ₹216 Cr | ₹194 Cr | ₹305 Cr | ₹267 Cr | ₹281 Cr | +6.8% |
| EPS (diluted) | ₹12.81 | ₹11.66 | ₹18.58 | — | — | +9.7% |
| CFO | ₹162 Cr | ₹155 Cr | ₹221 Cr | ₹318 Cr | ₹200 Cr | +5.5% |
| CapEx | ₹-133 Cr | ₹-113 Cr | ₹-93.4 Cr | ₹-96.7 Cr | ₹-187 Cr | — |
| FCF | ₹29.1 Cr | ₹41.8 Cr | ₹127 Cr | ₹221 Cr | ₹13.9 Cr | -16.9% |
| Total Assets | ₹2270 Cr | ₹2343 Cr | ₹2468 Cr | ₹2714 Cr | ₹2919 Cr | +6.5% |
| Total Debt | ₹32.2 Cr | ₹28.3 Cr | ₹20.5 Cr | ₹21.2 Cr | ₹15.5 Cr | -16.8% |
| Shareholders' Equity | ₹1957 Cr | ₹1982 Cr | ₹2097 Cr | ₹2281 Cr | ₹2485 Cr | +6.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
FDC vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
AARTIPHARM AARTIPHARM | — | — | Pending | 8.2% | — |
 SUVEN SUVEN | — | — | Pending | — | — |
SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
 SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
PGHL PGHL | — | — | Pending | 3.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
4 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹10.00/sh
Last payout
2026-02-11
₹5.00
Peak payout
₹5.00
Trailing yield
1.18%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. FDC LIMITED (FDC.NS) trades at 422.00 vs a model fair value of 544.66, a gap of 29.1%. Piotroski F-score: 7/9. Moat label: Moderate. Reve...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of FDC →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for FDC →
Compare
Head-to-head with peers
Compare FDC side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse FDCNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.